Key points: Physiological changes during pregnancy can reduce antiretroviral drug exposure and may increase the risk of HIV transmission to the infant. Our findings support the use of raltegravir in standard dosages in HIV-infected pregnant women to prevent mother-to-child HIV transmission. 
A c c e p t e d M a n u s c r i p t Introduction An estimated 1.4 million pregnant women infected with HIV give birth annually worldwide, of which the majority live in Sub-Saharan Africa. [1] Mother-to-child HIV transmission (MTCT) is the most common route of HIV-infection among infants and children. Each day, approximately 1,000 infants acquire HIV due to MTCT during pregnancy, delivery or breastfeeding.
Combination antiretroviral therapy (cART) is the standard of care for the prevention of perinatal transmission. The main goal of cART is maximal suppression of HIV replication. Its implementation together with other effective interventions has led to dramatic declines in the number of perinatally HIV-infected children from 15-40% to <2%. Absent or delayed prenatal care, acute primary infection in late pregnancy, and the continued increase in incidence of HIV infection in women of childbearing age are among the most important obstacles to fully eliminate perinatal transmission in the United
States and other resource-rich countries. [2] In current US and European treatment guidelines for HIV-1 infection in pregnancy, preferred combined antiretroviral agents include two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in combination with the protease inhibitors (PIs) lopinavir or atazanavir boosted with ritonavir or the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine. Regimens including the HIV-1 integrase inhibitor raltegravir can be considered for use in special circumstances because information on the pharmacokinetics and the safety of raltegravir in pregnancy is limited.
Examples of these special circumstances could be pregnant women who present late in care (>28 weeks gestational age) or whose HIV RNA load is not undetectable at third trimester. [2] [3] [4] HIV integrase inhibitors such as raltegravir have demonstrated to rapidly reduce HIV RNA load with shorter times to achieve virological suppression compared to agents from other drug classes. [5] Case reports and small case series suggest that raltegravir could play an important role when a rapid decline in maternal plasma HIV RNA is needed to prevent MTCT during delivery or as an alternative antiretroviral drug in complex treatment-experienced HIV-infected pregnant women. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In a pilot A c c e p t e d M a n u s c r i p t 5 study including 28 pregnant HIV-infected women, which was presented as abstract at a conference, the use of raltegravir seemed safe in both women and infants. [18] Pregnancy is associated with considerable physiological changes such as changes in gastrointestinal, hepatic, and renal function as well as alterations in the expression and activity of transport proteins and metabolic enzymes. Pregnancy may influence the pharmacokinetic profile of antiretroviral agents and lead to decreased drug exposure. Suboptimal drug exposure can result in HIV RNA rebound, the selection of resistant virus and an increased risk of HIV-1 transmission to the infant. [19, 20] Published information on the pharmacokinetics of raltegravir during pregnancy is limited. [21, 22] Watts et al. describe a 50% reduction in median exposure to raltegravir during pregnancy compared to postpartum and a large variability in raltegravir pharmacokinetics. The authors report that 92% of women had an HIV RNA load of <400 copies/mL at delivery and none of the infants were confirmed to be infected. Additional well-controlled studies are needed to confirm that raltegravir can be used safely in this special patient population. We studied the effect of pregnancy on the pharmacokinetics of raltegravir and its safety and efficacy in pregnant HIV-infected women.
Methods

Study design and participants
This multi-centre, phase IV study was designed as a non-randomised, open-label trial in HIV-infected pregnant women and coordinated by the PANNA network study group. The PANNA network is a European network of 19 hospitals in seven countries with the primary aim to collect pharmacokinetic data during pregnancy on antiretroviral agents for which no or limited data are available (www.pannastudy.com). We enrolled HIV-infected pregnant women (aged ≥18 years) who were on a cART regimen containing raltegravir 400 mg twice daily. Patients were eligible for inclusion if they were on raltegravir treatment for at least two weeks prior to the first pharmacokinetic assessment in the third trimester of pregnancy. Exclusion criteria were a medical history or current condition that might interfere with drug absorption, distribution, metabolism or excretion (such as renal failure or the area under the plasma concentration-time curve from 0 to 12 hours after intake using the trapezoidal rule (AUC0-12h), the trough concentration (C12h) defined as the sample taken at 12 hours, the maximum plasma concentration of the drug (Cmax), the time to reach Cmax (Tmax), the apparent volume of distribution (V/F), the apparent oral clearance being the dose divided by AUC0-12h (CLss/F) and the apparent elimination half life (Thalf). Patients from whom a curve was taken during pregnancy were included in demographic, safety analyses and descriptive statistics of the pharmacokinetic parameters. Pharmacokinetic parameters are reported as geometric means with 95% confidence intervals (CI). We calculated geometric means ratios (GMRs) and 90% CI of raltegravir pharmacokinetic parameters of third trimester versus postpartum using a mixed effects model in WinNonlin/Phoenix. Cord blood/maternal blood plasma concentration ratios were determined and described.
Results
Twenty-two HIV-infected pregnant women receiving raltegravir 400 mg twice daily were enrolled in Exposure to raltegravir, which is expressed as AUC0-12h, was 29% lower in the third trimester compared to postpartum by intrasubject comparison. Cmax and C12h were on average 18% and 36% No congenital abnormalities were reported. Five patients reported a total of ten adverse events which were considered not or unlikely related to the cART given. Seven events were grade 1 or 2.
Grade 3 neuropatic pain was reported as a serious adverse event not related to the use of raltegravir.
Other grade 3 adverse events were severe anaemia due to haemorrhagic delivery and varicella lesions.
Twenty-two infants were born and they were all tested HIV-negative. Three infants (14%) were small for gestational age (below 10th percentile of fetal-infant growth chart by Fenton [25] ), which is higher than observed in the US for children born from HIV-infected women (7.3%). [26] Other pregnancy outcomes are shown in 
Discussion
In this study we evaluated the effect of pregnancy on the pharmacokinetics of raltegravir and its safety and efficacy in 22 HIV-infected women. In the third trimester of pregnancy systemic exposure (AUC) to raltegravir was on average 29% lower compared to postpartum. However, pharmacokinetics of raltegravir was highly variable and exposure was not consistently decreased in third trimester compared to postpartum. Of the 17 women with paired pharmacokinetic curves six (35%) had a higher AUC0-12h in third trimester. A similar effect of pregnancy on C12h plasma levels was observed, leading to an average decrease of 36 % of the plasma levels seen postpartum. The magnitude of the observed effect is not considered to be of clinical importance. Similar effects of drug-interacting agents on the pharmacokinetics of raltegravir are described in the product information leaflet without special recommendation to adjust the dosage of raltegravir. [27] Viral suppression was good in our population with an HIV RNA load <400 copies/mL in all women and <50 copies/mL in 84% of women prior to delivery. The women (14%) who failed to have an undetectable viral load prior to delivery had adequate C12h levels in third trimester. Only one patient had a C12h level below 0.020 mg/L in third trimester, which is considered to be too low for adequate virological response in treatment-naive patients. [24] She had an undetectable viral load on the day of delivery.
The decrease in AUC (29%) in third trimester compared to postpartum was in line with the observations in a previous study with intensive pharmacokinetics of raltegravir during pregnancy from Watts et al.. [21] They describe a more pronounced decrease of approximately 50% in AUC in third trimester compared to postpartum. Given the high rate of viral suppression at delivery and the Raltegravir was well tolerated during pregnancy and all of the children were tested HIV-negative.
Only nine babies were exposed to raltegravir during the first trimester, with no birth defects reported. To assess prevalence rates of birth defects in infants exposed to raltegravir compared to non-exposed infants, more experience of raltegravir in human pregnancy is needed. Placental transfer of raltegravir is efficient with a median raltegravir CB/maternal plasma ratio of 1.21 in agreement with previous reports. [12, 13, 21, 32, 33] Unfortunately the collection of neonatal blood samples to describe the washout pharmacokinetics and safety of in utero exposure to raltegravir was not part of this study. UGT1A1 neonatal enzyme activity is still immature after birth and leads to prolonged elimination of raltegravir post-delivery. In newborns whose mothers were exposed to raltegravir during pregnancy raltegravir is slowly metabolized with an elimination half life that is highly variable. [9, 12, 33] In conclusion, raltegravir was well tolerated during pregnancy in our study population. Raltegravir pharmacokinetics showed extensive inter-and intra-individual variability. Our findings show a mean decrease in exposure to raltegravir during third trimester compared to postpartum which is not considered to be of clinical importance. Raltegravir in combination with other antiretroviral agents was effective in preventing MTCT by reducing and/or maintaining HIV RNA viral load at an undetectable (<50 copies/mL) or low level (<400 copies/mL). Our data support the use of raltegravir in standard dosages in HIV-infected pregnant women for the prevention of MTCT.
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